newsfilter
← Latest News
Business Wire·

Magenta Therapeutics Announces IND Clearance for MGTA-117 Targeted Conditioning Clinical Trial

– Phase 1/2 clinical trial expected to open in Q4 2021 in patients with relapsed/refractory acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) – Magenta Therapeutics, Inc. (NASDAQ:MGTA), a clinical-stage biotechnology company deve